Latest Fy2026 Results News

Vaughan Nelson Global Equity SMID Fund delivered a sharp rise in operating profit and more than quadrupled its net assets in FY2026, helped by $31.8 million in investment gains and strong investor applications. The result also leaves the ASX-listed Class B units with greater exposure to global equity and currency movements.

WasteCo is asking eligible New Zealand shareholders for up to NZ$750,000 in fresh equity as it tackles NZ$40.1 million of debt, a FY2026 loss and an aggressive operational reset. The non-underwritten plan follows a separate placement and is priced at NZ$0.007 per share.

Discovery Alaska Limited posted a $459,211 loss for FY2026 amid exploration write-offs and ongoing project development. The company secured $354,000 in a private placement and lined up a $900,000 placement to fund its Idaho and Western Australia gold-silver ventures.

Adherium's FY2026 results show strong revenue gains from US remote patient monitoring but increased losses due to higher operating costs and commercial expansion.

WT Financial Group (ASX: WTL) posted six consecutive years of growth in FY2026, with net revenue rising 15.6% to $33.1 million and EBITDA up 19.5% to $8.2 million, underpinned by its adviser network expansion and capital partnerships.

archTIS Limited’s FY2026 results reveal a 120% surge in sales revenue to $13.35 million, fueled by the Spirion acquisition, yet losses ballooned to $16.3 million reflecting higher operating costs and integration expenses.

CurveBeam AI’s FY2026 results show a 28% revenue decline and a 12% increase in net loss, while advancing its China commercialisation and robotic surgery integration strategies. The company also announced a $6-7 million capital raise post-year-end.

Cobram Estate Olives (ASX:CBO) posted an 11.3% revenue increase to A$268.9 million in FY2026 but swung to a A$4.2 million net loss as costs surged and integration expenses weighed. The company declared a steady fully franked dividend of 4.5 cents per share.

Syntara Limited’s FY2026 results show a 7.9% revenue decline and a 13.6% increase in net loss amid significant clinical progress, including FDA backing for its lead drug amsulostat and a successful $8.8 million capital raise.

Count Limited (ASX:CUP) reported a 71% jump in net profit to $15.2 million for FY2026, driven by strong organic growth and strategic acquisitions including the completion of Oracle Group. The company declared a fully franked final dividend of 3 cents, lifting total dividends to 5 cents per share.

Racura Oncology's FY2026 results reveal a widening loss despite a 22% revenue dip, underpinned by significant scientific progress on its lead drug targeting the elusive MYC gene and a robust $34.3 million cash position.

Aurizon launches a $250 million on-market share buy-back starting September 2026, signalling confidence in its financial outlook and disciplined capital management following a strong FY2026 performance.